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To understand how proteins function inside a cell requires the
analysis of their interactions with other molecules, including
other proteins. While many protein–protein interactions are
largely constitutive, for example those involved in the
makeup of molecular machineries such as the ribosome,
many interactions are modulated in a condition dependent
manner, including those regulated by post-translational
modifications [1]. While characterization of complex interac-
tion networks requires only identification of these proteins,
obtaining a dynamic view of the interactome necessitates
quantitative analysis.
Several approaches have been developed to identify
protein–protein interactions. These include enrichment pro-
cedures, of which an affinity-tagging protein purification (AP)
is the most common, as well as approaches based on the use
of reporter expression or visualization. As reviewed else-
where, these latter methods include yeast two-hybrid ap-
proaches and related technologies based on the protein
reconstitution brought upon by interaction of fusion partners,
as well as fluorescence or bioluminescence transfer ap-
proaches between two proteins in close proximity (FRET and
BRET) [2]. However, only a few of these techniques are
compatible with monitoring dynamically regulated protein–
protein interactions in a semi-quantitative or quantitative
manner. Many of the methods available for probing the
dynamic nature of protein interactions couple affinity purifi-
cation with a detection strategy compatible with quantifica-
tion. For example, one particularly suitable approach to
analyze interaction dynamics, LUMIER, has coupled affinity
purification (of a bait protein) with detection of a prey protein
via luminescence measurements, the prey protein being in
this case fused to a luciferase protein [3].
Protein quantification and expression analysis have been
performed for many years. Techniques such as immunoassay
(enzyme-linked immunosorbent assay; ELISA) and immuno-
blotting (commonly known as Western blotting) have been
used to provide quantification of biomolecules [4]. However,
antibody-based measurements require the development of
specific antibodies to the biomolecule of interest, which can
be both time-consuming and costly, although we note that
several collaborative projects aim at generating affinity re-
agents to every protein [5–7]. In particular, accurate quantifi-
cation based on antibodies requires the generation and
validation of high-quality reagents, which can be a long and
expensive process. It is also impractical to generate an
antibody library to every form of a protein, e.g. splice variants
and post-translationally modified forms, especially as the
knowledge of modified forms is constantly growing. Further-
more, although significant progress has been accomplished in
multiplexing antibody-based assays [8–12], the approach still
has clear limits as to the number of proteins that can be
assessed simultaneously. This, together with a lack of
appropriate antibodies to a large number of proteins means
that the use of Western blots or ELISAs for protein network
level quantification is not practical. Besides issues of avail-
ability and multiplexing, there are additional issues related
to relying on antibodies for quantification. For example,cross-reactivity with other proteins (for example when the
epitope recognized by the antibody is not known) may affect
the quantification. In the case of protein–protein interaction
studies, the epitope recognized by the antibody may addi-
tionally overlap with the binding site for one or more proteins,
resulting in an underestimation of the protein abundance
and/or the displacement of protein interactions.
As an alternative to ELISA or Western blot methods, there
has been a gradual shift towards using mass spectrometry as
a method to simultaneously identify and quantify proteins in
samples [13,14]. Mass spectrometry has allowed the develop-
ment of highly multiplexed quantitation assays, providing a
mechanism for their rapid development without many of the
issues or the long lead-time of antibody based methods. LC–
MS/MS has also increased the understanding of how protein
isoforms and post-translational modifications (PTMs) control
and regulate multiple cellular processes.
In the case of interaction proteomics, affinity purification
has been coupled to a variety of quantitative mass spectrom-
etry approaches. For the purpose of this discussion, we
categorize the mass spectrometry acquisition strategies into
“Data-Dependent Acquisition”, DDA, or “Data-Independent
Acquisition”, DIA. By far the most common use of DDA is for
identification of compounds through “shotgun” techniques.
In these experiments, a parent ion is chosen for fragmenta-
tion based on a simple set of heuristic rules, usually parent
ion intensity, and the MS/MS spectra derived from the
selected parent ions are utilized for identification (Fig. 1). By
contrast, data independent acquisition does not select ions to
be fragmented based on information in the precursor ion
scan, and true DIA approaches aim at fragmenting the entire
set of precursor ions in the visible range of the mass
spectrometer. As discussed in detail below, this distinction
between the selection of ions for fragmentation has important
impacts in the resulting quantification.
Continual innovations in mass spectrometric instruments
have resulted in dramatic improvements in the sensitivity of
detection, allowing the detection of lower level components
within samples. Besides being able to see deeper into samples,
sensitivity improvements allow an increase in the scanning
speed of instruments, which has opened the potential to use
different workflows and methods for quantitation and iden-
tification. Here we discuss approaches for quantitation of
peptides and proteins, especially as they apply to the analysis
of protein–protein interactions detected from the coupling of
affinity purification and mass spectrometry (AP–MS). These
approaches are also applicable to a variety of other sample
types covering different application areas where quantitation
is needed, however the sample complexity ultimately dictates
which methods can be employed.2. MS intensity or count-based data
dependent methods
An efficient way to perform quantification of peptides and
proteins is to incorporate a differential isotopic (or in some
case isobaric) labeling strategy into the experimental pipeline.
Usually, labeled and unlabeled samples are mixed prior to
analysis so compound ratios can be determined directly by
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Fig. 1 – Schematic depiction of a typical “shotgun” experiment in a QqTOF instrument. The instrument cycles between 2
different scan modes. (A) In the first mode (MS1) all ions are transmitted through the instrument and detected at the detector
which can be subsequently used for parent ion are determinations. The derived MS spectrum is analyzed using simple rules
(intensity, charge state and whether the ion has been fragmented before). Ions which pass these simple rules are then isolated
and fragmented. (B) In MS/MS mode, specific masses are isolated in the first quadrupole and fragmented in the second. All of
the fragment ions are recorded in the analyzer and a MS/MS spectrum generated which can be used for compound
identification.
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broadly grouped as those which are covalently attached to
peptides, e.g. isotope coded affinity tags, ICAT [15] or iTRAQ
[16], incorporated through enzymatic reactions, e.g. incorpo-
ration of 18O via trypsinization [17], or metabolically incorpo-
rated, e.g. stable isotope labeling with amino acids in cell
culture, SILAC [18]. In the context of protein–protein in-
teractions, labeling approaches have most often been used
for the identification of background nonspecific binding
proteins, but are also appropriate to monitor regulated
interactions, as recently reviewed [19]. In general, techniques
based on isotope labeling provide excellent results, though
recently a number of issues have been documented which
relate to the quality of the quantitative measurements [20],
that coupled with long assay development times and issues of
scaling to appropriate sample sizes limit the utility of such
techniques.
The recent resurgence in label-free approaches has placed
different requirements on the analytical methods employed.
Conceptually, spectral counting is the simplest label-free
analysis method [21,22]. In an identification experiment
(shotgun experiment), the number of MS/MS events triggered
for a single peptide can be summed: this sum corresponds to
spectral counts, which can be tabulated at the peptide and
protein level. Ultimately, the comparison of the relative
abundance of a protein across samples is achieved by
comparing the spectral counts for all peptides associated
with this protein in the different samples [23,24]. In interac-
tion proteomics, spectral counting and related approaches(such as counting the number of unique peptides, with or
without normalization, e.g. for protein length, [25] or even
using composite scores [26,27]), have been used to discrimi-
nate true interactions from non specific binding proteins, or to
identify major differences in the interactions between differ-
ent proteins [23,28–31]. We refer the readers to an excellent
review on data analysis of AP–MS data using counting
approaches for an in-depth discussion of the issue [24,32,33].
To provide reliable information, counting methods do
require an instrument that has the ability to sample a LC peak
at a high frequency, and therefore the faster the instrument,
the higher quality the spectral counting data [34]. Spectral
counting approaches are also strongly influenced by the
acquisition methods, in particular those which are normally
optimized to limit the number of MS/MS events for an
individual peptide, such as the dynamic exclusion parame-
ters and the exclusion width. Lastly, as the peak is being
sampled more than once, the identification dynamic range is
limited, and low-level ions may be missed in preference to
the higher intensity ions, limiting the application of spectral
counting to moderately to highly abundant proteins, or to
proteins whose abundance varies significantly between the
samples. Counting approaches are therefore not always appro-
priate for many important dynamically-regulated interactions.
Area measurements from the intensity of the signal
detected in the MS1 scan may be used to provide quantitative
information: the mass of interest is extracted across a time
domain, resulting in an extracted ion chromatogram (XIC),
which is used to integrate the LC elution peak of the
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processing SILAC data where intensity of spectral peaks of the
isotopically codes pairs are determined. The primary difference
between theseMS1-based label-free approaches and an isotopic
labeling approach is that retention time in LC space has to be
managed more closely, either by the incorporation of retention
time markers or through algorithms which will realign data on
retention time. Misalignment may also be mitigated by the use
of modern LC systems, which have very good reproducibility in
elution, but even in these cases the complexity of proteomic
samples may give rise to misalignment. For accurate definition
of an LC elution peak, the scan rate of the instrument is
important, as insufficient measurements can significantly
affect the area determinations (Fig. 2). Although not explicitly
shown on Fig. 2 the reduction of the number of data points
across a LC peak can clearly reduce the definition of the peak
apex and affect the area determination. The quality of the
quantification can also be problematic in shotgun sequencing
workflows in which the frequency of the MS1 scans is
affected by the selection of ions to fragment and the time
spent in sequencing each precursor. This being said, newer
generation instruments are able to collect a large number of
MS/MS events and also maintain a consistent number of
points across the LC elution peak, therefore providing reliable
MS1-based quantitation.
In general, MS1-based quantification has been performed
hand in hand with identification, in which only the identified
species are quantified. However, this requirement for simul-
taneous identification is not absolute: for example, MS1
quantification is widely used in metabolomics without MS/
MS measurements for the identification of the compoundsMS Cycle Time
Peak Width at Half Height
Chromatograph Peak Width
Fig. 2 – The number of points which are used to determine
the peak shape is critical to the quantitation reproducibility.
The balance between the cycle time and peakwidth is critical
for determining the chromatographic peak shape. The
recommended minimum number of points used to define
the LC peak shape is 8, which should provide a good
estimate of the peak apex. The cycle time is a balance
between accumulation time and number of ions monitored/
fragmented. In the case of Shotgun proteomics, the LC peak
is sampled infrequently, whilst this sampling frequency
increase in SRM analysis. It is important to not only have a
large number of points to define a peak but the points
themselves should be equidistant also.[35–37]. In this case, MS1 chromatographic peaks are aligned
across samples, and areas are profiled. In proteomics, a
similar data reduction process can be employed that consists
in aligning MS1 data by mass and retention time across
different samples followed by statistical processing to identify
masses that show biologically significant differences [38,39].
This data processing scheme has been enhanced by the
prediction of peptide retention times [40], allowing subse-
quent identification of compounds in the absence of MS/MS.
Within the context of interaction proteomics, an intermediate
strategy has also been proposed [41] where identification
results from pooled reference samples can be used to target
MS1 data extraction and subsequent quantification. This
hybrid method allows the extraction of data from the sample
in a semi-targeted fashion and inmany cases does not require
the complex alignment of LC–MS traces.
Although MS1 based methods generally provide relatively
accurate quantitation and are rapid, there are a number of
issues with the technique. Firstly, when “identified” com-
pounds are not used to target data extraction, the alignment
of different MS1 LC peaks across multiple samples requires
complex algorithms [42,43]. Furthermore, when all measured
MS1 masses are extracted from complex samples, the
potential for overlapping spectral peaks between samples is
increased, resulting in convolved data both at the spectral and
LC level. Secondly, sample complexity, the specificity of the
detection device and also the number of times a LC peak is
sampled by a MS1 scan govern the limit of detection (LOD) by
introducing a level of noise that cannot be separated from the
parent ion signal for lower intensity species. High-resolution
mass spectrometry has been used to reduce this effect,
however there is a limit to what can be separated by
resolution alone. Spengler et al. showed that resolution allows
for the identification of peptide elemental compositions [44],
but many peptides can have the same chemical composition
and therefore an orthogonal technique is needed to separate
the compounds. These factors, coupled with technologies to
limit the number of ions entering the detection system, e.g.
Automatic Gain Control (AGC), can result in compounds not
being detected in all samples or the error of low intensity ions
being greater than acceptable.
Experimental methods have been used to mitigate these
issues. One common method is sample fractionation, i.e.
cation exchange separation [45], or the use of longer LC
gradients with long columns [46,47]. In all cases, the aim is to
minimize as many interferences within a LC–MS peak as
possible, thus enabling more accurate measurements of the
peptide content of a sample. However, if multidimensional
fragmentation is used, it is common to identify the same
species in multiple fractions, rendering quantification more
complicated. This can be corrected by software, but the
processing of fractionated label-free samples remains a
challenging problem [48]. This being said, MS1 quantification
of AP samples is usually possible in a single LC–MS/MS
analysis, as sample complexity is less of an issue, and has in
fact been applied to discriminate between true interactions
and background noise [49,24,30]. We and others have also
successfully used affinity purification combined with parent
ion area extractions to quantify differential protein interac-
tions [50].
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label-free) suffer from the same issue — under sampling of
the injected sample that results from the stochastic nature of
the DDA method. In DDA experiments, it can be difficult to
determine if the absence of a peak area is due to the absence
of a compound or if whether it is related to the random nature
of detection. This phenomenon increases the measurement
variability within a system, lowering confidence in the
measurements closest to the detection limits. As protein–
protein interaction studies generally involve proteins at all
levels of abundance in the mixture (depending on their
relative association with the “bait” protein which is being
purified), this randomness limits the amount of network
coverage that can be achieved. In attempt to minimize the
under sampling effect, different quantitative methods have
been developed, which target specific compounds and use
MS/MS as ameans to improve the selectivity and specificity of
the detection; these are discussed below.3. MS/MS based and data
independent methods
There has been a trend to improve the analytical rigor within
peptide-based quantitation experiments, and terms such as
“limit of detection” and “limit of quantification” are nowwidely
employed. The use of MS/MS quantitation methods such as
Selected Reaction Monitoring (SRM) has provided data that
has higher specificity and selectivity than direct parent ion
measurements. Furthermore, techniques for data processingQ1
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Fig. 3 – Schematic depiction of SRMmeasurements. (A) Parent ion
a mass resolution of 0.5–0.7 amu. The ions are transmitted to th
fragmentation and fragment ions are transferred to the third qua
resolution of 0.5–0.7 amu. This allows the transmission of specif
measurement. (B) Selected fragment ions to be monitored by SRM
isolation window. Fragment ions at high resolution are shown w
each extraction window. The window to the left and also to the r
the window in themiddle shows an interfered ion. In this case, it
higher variance than the other ion.developed for drug analysis have brought higher degree of
analytical rigor to the field of MS-based quantification.
The most commonly used MS/MS-based quantification
approach, SRM (Fig. 3A), is routinely used in the pharmaceu-
tical industry for bioanalytical studies ofmultiple compounds,
including peptides [51]. As shown in Fig. 3A, SRM is generally
performed in a triple quadrupole instrument where a parent
molecule is isolated, fragmented and a fragment ion isolated
in the final quadrupole, providing superior selectivity of this
technique over MS1-based methods [14]. Modern instruments
are able to repeat these measurements on the order of 1000
times a second, allowing for the analysis of a vast number of
transitions (a term given to the combination of Q1 and Q3
isolation masses) (Fig. 3A).
SRM methods are not normally considered data indepen-
dent in the strict sense of the term, but more commonly
referred to as “targeted” methods as a list of compounds of
interest must be predefined at the onset of the experiment. A
targeted SRM assay requires information about the fragmen-
tation of the peptide to be measured and, optimally, its LC
retention time. Information about the fragmentation of
compounds within the sample is used to define the method;
this requires a certain level of iteration to generate the highest
quality of quantitative data [52]. In all cases, SRM acquires
data whether or not the parent ion is detected and a signal
derived, from either background noise or real signal. In
contrast to DDA-based methods where the detection is semi
random, based on the parent ion mass being selected for
fragmentation, SRM enables unbiased measurements of
compounds at the lower limits of detection since it performsCID Q3
 
s of interest are isolated in the first quadrupole, usually with
e collision cell where they undergo collision induced
drupole, which is also operated in a mass selection mode at a
ic fragment ions, which are detected as a single ion intensity
are shown by the shaded boxes that represent a 0.7 amu
ithin these boxes to represent the true ion population within
ight show fragment ions which are not interfered with, while
is highly likely that the peakwill be convolved and result in a
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the removal of any stochastic effects. This allows SRM
measurements to achieve accuracy and precision levels that
are accepted by regulatory authorities and used in bioanalytical
laboratories for the analysis of biomolecules.
Acceptance of SRM measurements in proteomics was
facilitated with the development of hybrid technologies
which allowed the acquisition of high quality MS/MS spectra
triggered from SRM signals [52]. This novel combination of
mass spectrometry scanning methods provided ability to
perform measurements with a high degree of confidence
and enabled quantitation of a larger number of proteins
[53–55]. These studies all show that SRM provides measure-
ments that are both consistent and precise across a range of
samples and an extended period of time. Importantly, in a key
step towards the global adoption of SRM as a robust
quantification approach, a multisite validation of SRM assays
was undertaken by the CPTAC group [56], introducing
guidelines and a framework for SRM-based measurements
and highlighting the possibility of robust multiplexed protein
assays running on multiple instruments in many facilities.
These reports also identify some of the key issues with SRM
methods, namely the need for upfront assay validation and
iteration. For example, it is possible that method development
for a 100-protein assay takes more than 12 months to identify
the correct transitions and confirm the validity of the assay
ensuring that there are no “hidden” interferences in the SRM
signal (Fig. 3B). Reducing development time is critical if SRM is
to be utilized in more protein quantitation studies, especially
as modern instrumentation enabling fast SRMmeasurements
can monitor enough peptides to cover networks of up to 200
proteins. Within the context of interaction proteomics exper-
iments, SRM approaches may be most appropriate for cases
where the same bait (or small group of baits) and interactors
need to be profiled repeatedly across multiple conditions. For
example, Bisson et al. developed an SRM assay centered
around the key signaling scaffold protein GRB2 which they
then used to profile interaction dynamics following growth
factor addition [57]. Such SRM approaches would also enable
profiling interactions following the addition of therapeutics
and/or across cell lines or patient samples.
In most cases, proteomics assays do not require the full
validation of a regulated SRM assay, but analytical testing is
essential to ensure that the correct compound is being
measured. Analytical verification time has become a key
factor in the choice between SRM or other measurements, e.g.
spectral counting. Validation and verification of SRMmethods
centers on ensuring identification of the correct transition
signals (peak) and that the most appropriate transitions have
been used to gain optimal LOD. This can be a challenge for
SRM as the measured signal is derived from a range of
fragment mass space, typically 0.5 to 0.7 Da (Fig. 3B) having
implications on the selectivity of the measurements. Because
peptide fragment ions have similar elemental compositions,
MS/MS mass space is very crowded and it is likely that a
closely eluting species with a similar Q1/parent mass will also
have MS/MS ions or are close enough in mass space to also
occupy the Q3/fragment ion mass volume being targeted.
These convolved signals will be recorded in the data and
require algorithms and statistical approaches to deconvolutethe resulting LC–MS/MS signal traces. These issues also exist
in MS1 data, but in the case of SRM, a number of different ion
signals can be derived from the MS/MS spectra and tested to
identify a “clean” LC peakwhereas inMS1 there is only a single
signal that is either clean or convolved. The identification of
potentially convolved ions and selecting of non-convolved
alternatives extends SRMmethod development time as this is
generally amanual process, although commercial and publicly
available software can help identify potential outlier transi-
tions in an automated manner [58].
Extensions to the SRMmethod using subsequent fragmen-
tation of product ions in a process called MS3. This can be
used to enhance the selectivity for the targeted compound,
mitigating many of the effects described above. MS3 has been
used to great effect in lowering the limit of detection for the
analysis of peptides as described in Fortin et al. [59]. However,
the use of this method does come with some limitations,
primarily that the time required to perform the MS3 scan
reduces the number of peptides that can be monitored and/or
the number of points across the LC peak, and that the method
development time is extended beyond the time required to
develop the basic SRM assay.
As mentioned above, a limitation of SRM approaches to
date has been the requirement for the establishment of the
methods, that is the selection of the optimal transitions to be
monitored. To facilitate the development of assays, a growing
number of resources are becoming available that assist the
individual researchers in selecting transitions in a faster time,
including collections of spectral libraries derived from both
experimental shotgun data and also from the analysis of
synthetic peptides [60–63]. These resources are references for
SRM assays that enable faster implementation across plat-
forms and sample types [63]. However, the nature of the
synthetic libraries is such that the coverage for proteins is
somewhat limited, normally to 4 or 5 peptides per protein.
This is most often adequate for the quantification of protein
abundance, but usually not for the analysis of a particular
isoform or post-translationally modified form, limiting the
full utility of the libraries currently available.
Recently, SRM has been extended to modern instruments
with high-resolution second mass analyzers [64,65] that in
general collect a full MS/MS spectrum for all targeted
compounds. This allows post acquisition identification of
potential fragment ion interferences that would have been
masked with the use of quadrupole mass resolution (Fig. 4).
The use of high-resolution provides a method with signifi-
cantly higher specificity than classical SRM, and decreases
method development time, as only parent masses for the
targeted peptides are selected and all fragment ions and
interferences are detected in one analysis. The general
applicability of this approach has been impeded by the fact
that until recently it was not possible to schedule the analysis
of peptides in the high-resolution SRM measurements,
significantly limiting the number of ions that could be
measured in a single analysis. Instrument vendors further
report that in this mode, the limit of detection for complex
samples is better than those achieved by MS1 methods but
not as good as classical SRM measurements. Although the
sensitivity of classical SRM will likely remain better than that
of high resolution SRM for the foreseeable future, the ease of
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Fig. 4 – Schematic representation of high-resolution SRM and improved ion selection by using high-resolution extractions. As
in the case of SRM, parent ions are filtered in the first mass selection quadrupole and fragmented in a collision cell by collision
induced fragmentation (A). In this depiction a TOF analyzer is shown in which all product ions are measured at a resolution of
>20,000. Extraction of ions with narrow windows <0.05 amu from the resulting spectra (depicted by the shaded boxes)
provides high resolution XICs which should be free on interference.
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technology as a stepping-stone to performing classical SRM.
Furthermore, there may be situations where the extra speci-
ficity of the techniques provides improved detection limits.
As mentioned above, although classified here as data-
independent methods, SRM and derivatives are targeted
methods that require a list of known compounds and transi-
tions. This targeting means that as a hypothesis develops,
samples require reanalysis to target different compounds. In
many cases, samples which are being analyzed are either
expensive to generate or are irreplaceable, and therefore testing
new hypotheses may be impossible. Hence, there has been a
need for methods that allow the detection of all compound
fragment ions for quantification. It is important to differentiate
this concept from SRM, as data acquisition does not target
specific compounds. It is also noteworthy tomention that until
recently, the use of data independent analysis was focused on
protein identification and not protein quantification [66].
Over the past years, there have been many proposed
methods for the analysis of samples using true data indepen-
dent strategies, which in general fragment all compounds
that are within the isolation range of the mass spectrometer,
are ionizable at the source and also elute from the chromato-
graphic system. The methods described to date try to balance
the cycle time for data collection with the sample complexity
and gradient length and attempt to gain sufficient LC peak
definition by altering the specificity of parent ion selection.
Although methods such as MSE[66] and All Ion Fragmentation
(AIF) [67] use cycle times of about 2 seconds, they could in
theory scan at much faster cycle times. This form of DIA
utilizes a wide band pass filter for selection of ions and
subsequent fragmentation of all of the ions. In the case of MSE
or more recently HD-MSE, a TOF analyzer is used to detect the
fragment ions directly or after Ion mobility separation. AIF
utilizes a FT-based orbital trap instrument to detect the
fragment ions, and as such should offer higher detection
resolution. It should be noted that in these instruments,
increasing the residence time to improve the resolution
decreases the overall cycle time. The greatest concern with
such methods is the specificity of the fragment ion isolationafter fragmentation of wide swaths of parent ions that may
compromise their uniqueness.
Methods such asPAcIFIC [68] orMSMSALL improve theparent
ion selectivity by stepping the isolation window with a much
narrower mass filter, in comparison to the DIA approaches
outlined above. In the case of PAcIFIC, an isolation window of
2.5 amu is used to step across a small mass range e.g. 45 Da,
allowing the use of the technique for LC-based separations.
However, to cover the entire parent mass range, multiple
sample injections are required, extending the analysis time
significantly. In the case of MSMSALL, the ions are filtered in
0.7 amu steps, offering the highest parent ion selectivity but
with a concurrent long cycle time, resulting in this technique
being applied thus far primarily for infusion-based experi-
ments, such as lipid analysis [69].
Alternative DIA methods analyze a window of masses and
step thiswindowacross the completemass range of interest in
cycle times that are compatible with chromatography. These
methods balance the cycle time promised by AIF/MSE and the
selectivity of PAcIFIC/MSMSALL to provide methods which
allow a high degree of selectivity and fast LC compatible
cycle times (Fig. 5). Methods have been described for Ion Trap
[70] and also TOF [32] instruments, although the use of ion
traps for ion detection, while potentially useful for compound
identification [71], may be less applicable to quantification, as
this depends upon the analysis of non-convolved fragment
ions. The previous discussion about the use of SRM, and the
issues of co-eluting species generating ions which interfere
with the Q3 detection mass, also apply to the use of low
resolution fragment ion scans for DIA methods in which the
wider isolation window of the mass selection device allows
more ions into the detection system, compounding the
potential for fragment ion convolution.
Methods such as MS/MSALL with SWATH™ Acquisition on a
TOF instrument [32] and multiplexed DIA on quadrupole-
orbitrap instruments [72] appear to overcome the limitations
described above and offer stepped isolation windows with
sufficient speed to cover the compound mass range of interest.
Questions remain about the ability of these approaches to
maintain the specificity of compounds when compared to
CID Q1
SWATH™ Acquisition
TOF
m/z 
co
u
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ts
 
Fig. 5 – Schematic representation of SWATH DIA. Here, the first mass selection quadrupole isolates and transmits ions in a
defined window which will contain a number of different parent ions. This mixture of ions is fragmented in a collision cell by
collision induced fragmentation and transmitted to the TOF analyzer where all product ions are measured at resolution
>20,000. (B) Extraction of high resolution XICs, as in high resolution SRM, from the resulting mixed MS/MS spectra allows the
removal of potential interferences, providing specificity to the quantification results. The isolation window is stepped through
the entiremass range of interest: the number of windows, their width, themass range to be covered and also the accumulation
time all contribute to the total cycle time.
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unique ion signatures for peptide SRM data [73] showed that
prediction may be inappropriate using low resolution detection
scans, and recently Röst et al. highlighted the need for high
resolutiondetection scans [74] and also pointed to theneed for a
third factor to enable successful quantification of compounds
by DIA, namely retention time. In these studies, selectivity of
the signal detection was evaluated, indicating that techniques
such as SWATH do in fact provide selectivity similar to SRM.
At this point, it is not clearwhich instrument(s) are ideal for
DIA workflows. In the case of trap based detection systems,
the need to limit the number of ions analyzed in order to
mitigate space charge effects may reduce the quantitative
dynamic range, however space charge effects have recently
been shown to coalesce ions of similarmass into single spectra
peaks depending upon the intensity of the signal [75], further
impacting the quality of the data. TOF detection systems
provide lower resolution (~25,000) than that achieved by
FT-based instruments but their higher scan speeds allows
faster coverage of the mass range of interest, thereby
increasing the number of points across the chromatographic
peak and improving quantitation. TOF based detection sys-
tems also provide a linear dynamic range that is unaffected by
space charge and therefore could prove to be the superior
instrument for quantitative DIA.
The use of DIA will likely expand the utility of current
libraries and may provide impetus for further development of
public libraries. Library generation will likely be an area of
expansion, as more people adopt DIA-based quantification. In
addition, DIA provides a unique feature, namely a complete
digital MS/MS record of all compounds that are detectable
within the sample. This record allows a hypothesis to change
during a biological study, and hence data from libraries can be
used to probe samples for proteins which were not originally
targeted or identified within a sample.
Reinterpretation of data after acquisition was described by
Gillet et al. who used a SWATH data set to test different
hypotheses [32]. This ability of DIA methods opens newavenues for data sharing and testing, but also demands
greater information about the sample preparation and cell
line/type be stored [76] with the data in public repositories,
especially in the case of protein–protein interaction studies
where the experimental conditions are critical to understand-
ing the nature of the potential protein interactions.4. The future for protein–protein
interaction mapping?
With the increasing level of multiplexing available from
different MS based methods, the extent of protein interaction
networks that can be studied is increasing. More importantly
the emerging methods used for peptide and protein quanti-
tation generate data that is complete and unbiased - a
fundamental requirement for the study of complete networks
or interactomes.
It is clear that there will always be a role for the DDA based
methods; they are simple to perform and provide a rapid
assessment of the amount of material within a sample. Besides
simplicity, there will always be a need for the identification of
proteins as well as post-translational modifications. The extent
to which the biology of any protein is known in a dynamic
system is minimal, and the ever-increasing numbers of splice
variants, SNPs, etc. will likely mean that experiments where
both quantitation and identification are performed using DDA
methods or “discovery quantitation”will be the first method of
choice for the foreseeable future. However, the direct path from
IDA to a targeted DIA, e.g. SRM, appears to be changing. The
development of DIA methods that have the analytical perfor-
mance of SRM will result in data that can be used to test
multiple hypotheses, or even used in different experiments,
reducing the amount MS analyses required and changing the
emphasis to a bioinformatic issue.
What of SRM? It is clear that DIA methods published to
date still lack features that can be found in SRM methods.
Although selectivity and specificity are of concern in DIA
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Fig. 6 – Potential future experimental workflow. Potential workflow for the use of MS techniques in the quantification of
proteins. Initial hypotheses are developed from the identification of proteins within samples, where MS1 based techniques
may be used for quantification. Hypothesis verification requires a greater degree of confidence in the quantification, which is
gained by using DIA techniques. Methods such as SWATH allow the modification of hypotheses without the experimental
reanalysis of the samples, enabling further refinement of the hypothesis. Hypothesis validation could be performed using
methods such as SWATH but as the number of proteins to be monitored decreases with hypothesis refinement, analysis
methods can also change to routine monitoring as offered by SRM.
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issues have been addressed in the case of methods like
SWATH [74], yet the sensitivity of themethod appears to be an
order of magnitude lower than dedicated SRM [32]. It seems
likely that a workflow of experiment as shown in Fig. 6 will
emerge starting with a DDA based quantitation method such
as MS1 XICs followed by high multiplexing assays such as
SWATHwhere the largest number of proteins can be precisely
monitored in a single analysis. As hypotheses develop, the
number of proteins that require monitoring will reduce and
result in an assay that could be performed through high
resolution SRM and ultimately as a standard SRM assay on a
high sensitivity triple quadrupole based instrument. This
workflow provides a pipeline that starts with lower confi-
dence results and ends using robust and proven technology as
the final assay and may prove a future experimental pipeline
in biomarker discovery.
Although protein–protein interaction studies appear sim-
ple to perform, the data requirements for high quality
measurements are stringent. As the number of known protein
interactions increases, so does the number of proteins that
are required for analysis. This increase requires methods that
allow the quantitative analysis of proteins in a consistent
manner, and DIA methods provide the best sample coverage.
DIA also allows for the analysis of different proteins within a
data set without sample reinjection and therefore offers the
potential to accelerate the testing of multiple hypotheses in
experiments and will serve to accelerate the understanding of
how proteins interact in protein networks. In the end, while
there is no wrong method for protein quantitation, theselected method must balance performance, development
time and the analytical rigor required to the question being
asked, and to the biological sample studied. The emergence of
new modes of quantification potentially applicable to protein
interactions should enable the researcher to select the most
appropriate method (or methods) for their problem.Acknowledgments
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